Table 3.
Patient ID | Gender | Age at study entry | Diagnosis | Siteb | Most recent known OPV exposure | Virus | Excretion duration—no. of nucleotide changes |
---|---|---|---|---|---|---|---|
12-017 | F | 7 years | CVID | Tunisia | 6 years | Sabin 1 | 1 month—3 nucleotide changes |
12-007a | M | 11 years | MHC II deficiency | Tunisia | 1 month | Sabin 2 | 5 months excretion—9 nucleotide changes (0.9%) |
12-025 | F | 7 years | MHC II deficiency | Tunisia | Unknown | Sabin 3 | 1 month—3 mutations |
14-057 | M | 6 years | Agammaglobulinemia | Iran | 1 week | Sabin 2 | 1 month—no mutations |
14-108a | F | 10 months | MHC II deficiency | Iran | 6 months | Sabin 2 | 10 months excretion on study—12 nucleotide changes (1.2%) |
14-116a | M | 3 months | SCID | Iran | 2 months | Sabin 2 | 6 nucleotide changes (0.6%) |
14-117a | F | 1 year | SCID | Iran | 6 months | Sabin 2 | 10 nucleotide changes (1%) |
26-012 | M | 22 years | CVID | Ankara, Turkey | 7 years | Sabin 2 | <3 months—no nucleotide changes |
27-030 | F | 2.5 years | MHC II deficiency | Ankara, Turkey | 2 years | Sabin 3 | Sequence pending |
20-003 | M | 8 months | Agammaglobulinemia | Istanbul, Turkey | 6 months | Sabin 2 | 5 months excretion on study—3–4 nucleotide changes |
11-031a | F | 11 months | SCID | Izmir, Turkey | 6 months | Sabin 3 | 15 nucleotide changes |
19-021 | M | 13 years | CVID | Yekaterinburg, Russia | 5 years | Sabin 3 | No nucleotide changes |
19-023 | F | 6.5 years | Agammaglobulinemia | Yekaterinburg, Russia | Not known | Sabin 2 | No nucleotide changes |
OPV, oral poliovirus vaccine; CVID, common variable immune deficiency; SCID, severe combined immunodeficiency; M, male; F, female; PID, primary immunodeficiency; MHC, major histocompatibility complex.
aPatients with immunodeficiency-associated vaccine-derived polioviruses (iVDPV).
bCountries are organized in order of World Bank income classification (lower middle and upper middle income).